4D Molecular Therapeutics (FDMT) Return on Sales (2020 - 2024)
Historic Return on Sales for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 631.72%.
- 4D Molecular Therapeutics' Return on Sales rose 139822800.0% to 631.72% in Q3 2025 from the same period last year, while for Sep 2025 it was 1742.84%, marking a year-over-year increase of 66932200.0%. This contributed to the annual value of 4345.7% for FY2024, which is 43408500.0% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Return on Sales stood at 631.72% for Q3 2025, which was up 139822800.0% from 3639.8% recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Return on Sales peaked at 1698.53% during Q4 2023, and registered a low of 49650.0% during Q4 2024.
- Its 5-year average for Return on Sales is 4168.06%, with a median of 123.95% in 2023.
- In the last 5 years, 4D Molecular Therapeutics' Return on Sales tumbled by -513485300bps in 2024 and then skyrocketed by 139822800bps in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Return on Sales stood at 272.57% in 2021, then soared by 92bps to 21.96% in 2022, then surged by 7835bps to 1698.53% in 2023, then plummeted by -3023bps to 49650.0% in 2024, then soared by 99bps to 631.72% in 2025.
- Its Return on Sales stands at 631.72% for Q3 2025, versus 3639.8% for Q2 2025 and 3431.36% for Q1 2025.